1,264 karma · joined July 1, 2015
https://metr.org/blog/2025-03-19-measuring-ai-ability-to-com...
https://metr.org/blog/2025-07-14-how-does-time-horizon-vary-...
How would you put this on a graph?
LLMs from late 2024 were nearly worthless as coding agents, so given they have quadrupled in capability since then (exponential growth, btw), it's not surprising to see a modestly positive impact on SWE work.
Also, I'm noticing you're not explaining yourself :)
He's not against the technology, I think he's just feeling like there's a lot of potential that he's not quite grasping yet.
I get it.
One sentence pragraphs feel punchy.
It feels like you're writing copy for an Apple ad.
..but it only works when it's in another medium, in a shorter format. In this form, it's just exhausting.
I'd be interested in integrating this with bug systems of decisions / goals, with actions being comments on those bugs (for work purposes) instead of having a custom deciduous-only DB.
Is this meant to be open source? I don't see a LICENSE.
In this case, you have a regressive tax with a huge positive side effect due to taxing an externality. If the funds are also spread into progressive services it can be a net positive for all income brackets.
15^(1/35) = 1.11
1500^(1/35) = 1.34
Did the author maybe put a few extra zeros in their calculator when figuring out the annual revenue growth which would equal 15x over a 25 year span?
Bullet points I can forgive, it's a common blog post writing style. But the ranty prose here definitely has a whiff of silicon.
Tokens/week have gone up 23x year-over-year according to https://openrouter.ai/rankings. This is probably around $500M-1B in sales per year.
The real question is where the trajectory of this rocket ship is going. Will per-token pricing be a race to the bottom against budget chinese model providers? Will we see another 20x year year over the next 3 years, or will it level out sooner?
I don't see how OpenAI or Google can profit from drug discovery. It's nearly pure consumer surplus (where the drug companies and patients are the consumers).